Advertisement
UK markets close in 3 hours 13 minutes

  • FTSE 100

    8,116.79
    +37.93 (+0.47%)
     

  • FTSE 250

    19,809.83
    +207.85 (+1.06%)
     

  • AIM

    754.86
    +1.74 (+0.23%)
     

  • GBP/EUR

    1.1671
    +0.0014 (+0.12%)
     

  • GBP/USD

    1.2509
    -0.0002 (-0.01%)
     

  • Bitcoin GBP

    51,456.04
    +265.34 (+0.52%)
     

  • CMC Crypto 200

    1,385.96
    -10.57 (-0.76%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.41
    +0.84 (+1.01%)
     

  • GOLD FUTURES

    2,357.30
    +14.80 (+0.63%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,052.02
    +134.74 (+0.75%)
     

  • CAC 40

    8,044.70
    +28.05 (+0.35%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Novartis blocked from selling Neupogen copycat until September

Reuters - UK Focus

By Andrew Chung

NEW YORK, July 21 (Reuters) - Novartis AG (Xetra: 904278 - news) unit Sandoz must wait until September to sell Zarxio, the first biosimiar drug approved in the United States and a copycat version of Amgen (Hanover: AMG.HA - news) Inc's Neupogen, a U.S. appeals court said on Tuesday.

Ruling in a patent infringement lawsuit filed by Amgen (Xetra: 867900 - news) , the U.S. Court of Appeals for the Federal Circuit, the country's top patent court, said that it would maintain an injunction on the Sandoz drug until Sept. 2. (Reporting by Andrew Chung; Editing by Chizu Nomiyama)